PANW Stock Analysis & IQ Rating | Palo Alto Networks

PANW Price Performance

Wall Street Analysts Think Palo Alto (PANW) Is a Good Investment: Is It?. Based on the average brokerage recommendation (ABR) Palo Alto (PANW) should be added to ones portfolio. Wall Street analysts overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So is the stock worth buying?

Today

Exploring The Competitive Space: Microsoft Versus Industry Peers In Software. In the fast-paced and cutthroat world of business conducting thorough company analysis is essential for investors and industry experts. In this article we will undertake a comprehensive industry comparison evaluating Microsoft (NASDAQ:MSFT) in comparison to its major competitors within the Software industry. By analyzing crucial financial metrics market position and growth potential our objective is to provide valuable

Today

Rivian Builds AI Assistant To Run The Vehicle Not Just Talk. ) has spent nearly two years developing its own a project separate from its $5.8 billion technology joint venture with ).Rivian designed the assistant to integrate fully with vehicle controls rather than functioning as a simple infotainment chatbot.The team in Palo Alto built a flexible model-agnostic architecture and focused on software layers that coordinate workflows and manage control logic across systems TechCrunch on Tuesday.Al

Today

UiPath and Talkdesk join forces to transform customer experience journeys. NEW YORK and PALO ALTO Calif. Dec. 09 2025 (GLOBE NEWSWIRE) -- UiPath (NYSE:) a global leader in agentic automation today announced an integration with Talkdesk Inc. a leader in customer experience automation (CXA) to enable organizations to leverage automation to optimize the end-to-end customer journey enhancing efficiency accuracy and satisfaction.Using a standards-based Model Context Protocol (MCP) the integration com

Tue Dec 9, 2025

Palo Alto Networks Inc. (PANW) Is a Trending Stock: Facts to Know Before Betting on It. Zacks.com users have recently been watching Palo Alto (PANW) quite a bit. Thus it is worth knowing the facts that could determine the stocks prospects.

Mon Dec 8, 2025

Inquiry Into Microsofts Competitor Dynamics In Software Industry. In the dynamic and cutthroat world of business conducting thorough company analysis is essential for investors and industry experts. In this article we will undertake a comprehensive industry comparison evaluating Microsoft (NASDAQ:MSFT) and its primary competitors in the Software industry. By closely examining key financial metrics market position and growth prospects our aim is to provide valuable insights for investors and shed

Thu Dec 4, 2025

Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms. Key PointsCalifornia-based Palo Alto Investors sold 791879 shares of STAAR Surgical Company in the third quarter leading its position value to fall by $13.3 million.

Wed Dec 3, 2025

PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million?. Key PointsCalifornia-based Palo Alto Investors increased its stake in PTCT by 456144 shares in the third quarter adding approximately $33.1 million in value.

Wed Dec 3, 2025

Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?. Key PointsCalifornia-based Palo Alto Investors acquired 997698 DYN shares in the third quarter.

Wed Dec 3, 2025

ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting. Studies Demonstrate xCellSense® Platforms Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. PALO ALTO Calif. Dec. 3 2025 /PRNewswire/ -- ImpriMed a precision oncology CRO specializing in ex vivo drug sensitivity testing for hematologic...

Wed Dec 3, 2025